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Abstract
In type 2 diabetes, amyloid oligomers, chronic hyperglycemia, lipotoxicity, and pro-inflammatory cytokines are
detrimental to beta-cells, causing apoptosis and impaired insulin secretion. The histone acetyl transferase p300,
involved in remodeling of chromatin structure by epigenetic mechanisms, is a key ubiquitous activator of the
transcriptional machinery. In this study, we report that loss of p300 acetyl transferase activity and expression leads to
beta-cell apoptosis, and most importantly, that stress situations known to be associated with diabetes alter p300 levels
and functional integrity. We found that proteasomal degradation is the mechanism subserving p300 loss in beta-cells
exposed to hyperglycemia or pro-inflammatory cytokines. We also report that melatonin, a hormone produced in the
pineal gland and known to play key roles in beta-cell health, preserves p300 levels altered by these toxic conditions.
Collectively, these data imply an important role for p300 in the pathophysiology of diabetes.
Introduction
Pancreatic beta-cells synthesize and secrete insulin, the
key regulatory hormone of glucose metabolism through
its action to constrain hepatic glucose production and
stimulate glucose uptake in skeletal muscle and fat. Type
2 diabetes (T2D) is a metabolic disorder characterized by
a progressive deterioration of beta-cell mass and function
in the setting of insulin resistance. The beta-cell deficit
and beta-cell failure in T2D are likely related to beta-cell
stress and apoptosis1, 2 in response to a variety of stress
factors including amyloid deposits, chronic hyperglycemia
and hyperlipidemia, and/or low grade-inflammation. The
preservation of a functional beta-cell mass is essential to
maintain glucose homeostasis. Beta-cell function and
survival are controlled by fine regulation of gene
expression in response to physiological stimuli and
metabolic changes. Among the mechanisms involved in
gene regulation, remodeling of chromatin structure by
epigenetic mechanisms is a fundamental process. Histone
acetylation is a regulatory mechanism capable of mod-
ulating properties of chromatin and thus the competence
of the DNA template for transcriptional activation. His-
tone acetylation is catalyzed by the chromatin-modifying
enzymes lysine/histone acetyl transferases (HATs)3 and
the reversed deacetylation process by lysine/histone dea-
cetylases (KDACs or HDACs)4. Whereas accumulating
evidence suggests the importance of KDACs for the
maintenance of beta-cell function and survival5–7 (for
review, see Campbell et al.8), roles of HATs in beta-cells
and their alteration under pathophysiological conditions
remains little investigated.
Among the HAT family members, the co-activator p300
is a key component of the transcriptional machinery
involved in diverse biological processes, including differ-
entiation, development, proliferation9, and circadian
function10, but also in numerous pathophysiological
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processes, including several forms of cancers and cardiac
hypertrophy11, 12.
In beta-cells, p300 is recruited to the insulin gene pro-
moter in response to glucose via its interaction with the
transcription factors PDX-113, Beta-2, and E4714. P300
also regulates PDX-1 transcription in beta-cells via its
interaction with the Maturity Onset Diabetes of the
Young (MODY)-associated transcription factor KLF1115.
In patients with T2D carrying mutations for Beta-2/
NeuroD16 and PDX-117, the ability of beta-cells to pro-
duce sufficient amount of insulin is compromised. Inter-
estingly, mutations of these genes precisely affect the
p300-interacting domain16, 18, 19, suggesting that a defect
in p300 could be a cause for beta-cell dysfunction.
Recently, a computational analysis identified some T2D-
associated single nucleotide polymorphisms (SNPs) that
were located at transcription factor binding sites including
p300 (EP300)20, further suggesting a potential involve-
ment of p300 in the pathophysiology of T2D.
Whereas p300 appears as a central integrator of various
signaling pathways, the regulation and biological actions
of p300 in pancreatic beta-cells remain elusive. Here, we
sought to study the potential role of p300 in beta-cell
survival and to investigate its mechanism of regulation in
beta-cells exposed to stress situations known to be asso-
ciated with T2D.
Results
Loss of p300 acetyl transferase activity and expression
leads to beta-cell apoptosis
To evaluate whether p300 loss could play a role in
vulnerability of beta-cells to apoptosis, we treated INS-1E
cells with C646, a selective, potent and cell-permeable
inhibitor of p300 acetyl transferase activity21. As a control
of its efficacy, acetylation levels of Histones H3, targets of
p300, were diminished by 43% in C646-treated INS-1E
cells (P < 0.05; Fig. 1a). Inhibition of p300 acetyl trans-
ferase activity in INS-1E cells led to increased caspase-3
cleavage and histone H2AX phosphorylation, a marker of
beta-cell apoptosis22, and of beta-cell death-associated
DNA fragmentation23, respectively (Fig. 1a). In mouse
islets treated with C646, an increase in caspase-3 cleavage
was also clearly detected (Fig. 1b). To further confirm the
observation that p300 is important for beta-cell survival in
primary cells, we evaluated the frequency of TUNEL-
positive beta-cells in both isolated mouse and human
Fig. 1 Inhibition or knock-down of p300 leads to beta-cell apoptosis. a INS-1E cells were treated with C646 (30 μM for 24 h) (or with 0.003%
DMSO as vehicle). Levels of cleaved caspase-3 (Cl. Casp-3), Phospho-Histone H2A.X (Ser139) (pH2A.X) and acetyl-Histone H3 (Ac-H3) were assessed by
western blot. GAPDH was used as loading control. The graph represents the quantification of the western blot (n= 4). b Isolated mouse islets were
treated or not with C646 (30 μM for 48 h). Levels of cleaved caspase-3 (Cl. Casp-3) were assessed by western blot. Actin was used as loading control.
The graph represents the quantification of the western blot (n= 3). c INS-1E cells were transfected with scramble (Scr) or p300 siRNA (Si) (10 or 50
nM) during 48 h; (C, non-transfected cells). p300, CBP and cleaved caspase-3 (Cl. Casp-3) protein levels were analyzed by western blot. Actin was used
as loading control. The graphs represent the quantification of p300 and cleaved caspase-3 protein levels (n= 4). Data are expressed as mean ± SEM;
*P < 0.05, **P < 0.01, ***P < 0.001
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islets treated with C646. The frequency of TUNEL
staining in mouse beta-cells was increased by 2.7-fold in
islets treated with C646 (P < 0.05; Supplemental Fig. 1A
and B), whereas the frequency of TUNEL staining in
alpha-cells was not significantly different (Supplemental
Fig. 1B). Similarly, the frequency of TUNEL staining in
human beta-cells was increased by 1.6-fold under C646
treatment (Supplemental Fig. 1C and D). In addition,
inhibition of p300 by C646 also led to an altered beta-cell
function, as shown by the decreased expression of the
transcription factors Pdx1 and Nkx6.1 (Supplemental
Fig. 2A) and the decreased insulin stimulation index
(Supplemental Fig. 2B and C)
To further ascertain the involvement of p300 in beta-
cell survival and function, we used a siRNA approach to
specifically target p300 and decrease its expression.
Transfection of INS-1E cells using 10 nM and 50 nM of
siRNA for 48 h resulted in 51.6 ± 5% and 72.4 ± 3.7%
knockdown of p300 protein content, respectively (Fig. 1c).
The decrease in p300 protein content was associated with
a decrease in p300 activity, as shown by decreased acet-
ylation levels of Histones H3 (Supplemental Fig. 3). This
decrease in p300 protein content and activity resulted in
increased beta-cell apoptosis illustrated by the cleavage of
caspase-3 (Fig. 1c), but also in an alteration of beta-cell
function, as shown by the decreased insulin stimulation
index (Supplemental Fig. 4). In conclusion, both p300
inhibition and invalidation data reveal a novel role for
p300 in beta-cell function and survival.
Diabetes-related conditions induce a loss in p300 protein
levels in beta-cells
We next examined whether p300 levels could be
modulated in several conditions known to be associated
with T2D. The islets in T2D are characterized by the
presence of toxic oligomers of human islet amyloid
polypeptide (h-IAPP)24. Transgenic expression of h-IAPP
in mouse islets (h-TGmice) leads to development of diabetes
with an islet pathology that recapitulates features of beta-cell
demise in human T2D25. We examined islets of mice with
comparable expression of the oligomeric human form of
IAPP (h-TG) versus the soluble rodent form of IAPP (r-TG).
Toxic oligomers of h-IAPP form intracellularly in beta-cells
of h-TG but not r-TG mice, and h-TG but not r-TG mice
develop diabetes25. In the experiments presented in this
study, we used mice in a pre-diabetic state to avoid the
confounding effect of glucose toxicity (Supplemental
Table 1). Increased expression of h-IAPP led to 81.2 ± 4%
decrease in cytosolic p300, and 83.2 ± 11.2% decrease in
nuclear protein levels of p300 in comparison to r-TG mice,
as shown by subcellular fractionation (Fig. 2a and b). We
conclude that p300 is downregulated in an animal model
prone to develop diabetes, due at least in part to the pro-
pensity of h-IAPP to form toxic oligomers.
In T2D, chronic hyperglycemia is detrimental to beta-
cells. Glucotoxicity led to increased beta-cell apoptosis, as
shown by the cleavage of caspase-3 and PARP (poly(ADP-
ribose) polymerase) (Fig. 3a and b). Treatment of INS-1E
cells with 30mM glucose for 48 h led to a 33.5 ± 3.4%
decrease in p300 protein content (P < 0.001), while its
paralog CBP (CREB binding protein) remained unaffected
(Fig. 3a and b). Under these conditions, altered p300
protein levels were associated with decreased acetylation
of p300’s targets Histones H4 (Fig. 3a and b), suggesting a
decrease in p300 activity. To further confirm these results,
isolated human islets were exposed for 72 h to high glu-
cose. In human islets, p300 protein levels were decreased
to the same extent as observed in INS-1E cells (30%
decrease in p300 protein content; Fig. 3 and Fig. 4).
Importantly, p300 protein level alteration was exacerbated
under glucolipotoxicity conditions (30 mM glucose+ 0.5
mM palmitate), as shown by the 53.3 ± 6% decrease in
p300 protein levels (P < 0.001; Fig. 4) associated with the
emergence of cleaved caspase-3 (Fig. 4).
Fig. 2 Increased expression of h-IAPP decreases cytosolic and nuclear protein levels of p300 in mouse islets. a Islets isolated from 9 to 10
week-old WT (wild type, n= 6), r-TG (rodent-IAPP transgenic, n= 6), h-TG (pre-diabetic human-IAPP transgenic, n= 4) mice were subjected to
subcellular fractionation. Cytosolic and nuclear fractions resolved by SDS–PAGE and immunoblotted with anti-p300, anti-GAPDH (loading control for
cytosolic fraction), anti-PARP antibody (loading control for nuclear fraction). b Quantification of p300 protein levels (n= 3). Data are expressed as
mean ± SEM.; #P < 0.05 and ###P < 0.001 vs WT
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Chronic inflammation is a hallmark of type 1 diabetes,
and increased islet inflammation has also been reported in
T2D, affecting both beta-cell mass and insulin secretion26,
27. Pro-inflammatory cytokines, particularly interleukin-1β
(IL-1β), in combination with interferon-γ (IFN-γ) and/or
tumor necrosis factor-α (TNF-α), lead to a decline in beta-
cell function and survival. As expected, pro-inflammatory
cytokines led to beta-cell apoptosis, as shown by the clea-
vage of caspase-3 and PARP (Fig. 5a and b). Treatment of
INS-1E cells with the cytokine mixture for 24 h led to a
48.6 ± 6.5% decrease in p300 protein content, while its
paralog CBP remained unaffected (Fig. 5a and b). As
suggested by the decreased acetylation levels of Histones
H4 (Fig. 5a and b), alteration in p300 protein levels was
associated with a decreased in HAT activity.
Altogether, these data reveal that the diabetes environ-
ment alter p300 functional integrity in beta-cells.
Diabetic conditions contribute to the proteasomal
degradation of p300
To delineate further the mechanisms involved in p300
protein loss under diabetogenic situations, we evaluated
p300 gene expression. While p300 protein content was
decreased (Figs. 3 and 5), we found that p300 mRNA
Fig. 3 p300 and histone H4 acetylation levels are decreased under glucotoxicity in beta-cells. a INS-1E cells were exposed to 11 mM glucose
(G11) or 30 mM glucose (G30) during 48 h. Protein levels of p300, acetyl-Histone H4 (Ac-H4), cleaved caspase-3 (Cl. Casp-3), cleaved PARP (Cl. PARP)
and CBP (CREB-binding protein) were analyzed by western blot. GAPDH was used as loading control. b Quantification of p300, Ac-H4, Cl. Casp-3 and
CBP protein levels. Data are expressed as mean ± SEM (n= 3); **P < 0.01, ***P < 0.001
Fig. 4 p300 protein levels are decreased under gluco/lipotoxicity in human islets. Human islets were exposed to 5 mM glucose+ EtOH/BSA as
vehicle (G5), 5 mM glucose+ 0.5 mM palmitate, 30 mM glucose+ EtOH/BSA as vehicle (G30) or 30 mM glucose+ 0.5 mM palmitate during 72 h.
Protein levels of p300 and cleaved caspase-3 (Cl. Casp-3) were analyzed by western blot. GAPDH was used as loading control. Data are expressed as
mean ± SEM (n= 3); ***P < 0.001 vs G5
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levels were not altered in INS-1E cells exposed for 48 h to
high glucose (Fig. 6a), and were even increased in INS-1E
cells exposed for 24 h to pro-inflammatory cytokines
(Fig. 6b). Interestingly, beta-cell and islet transcriptome
analysis in T2D subjects from two independent data sets
also revealed no change in p300 mRNA levels compared
to normal glycemic controls (GEO: GSE2096628 and
GEO: GSE38642;29 Fig. 6c and d, respectively). To eval-
uate whether p300 protein levels are altered in T2D, we
examined pancreatic tissue from human subjects with
T2D versus BMI-matched control subjects (Supplemental
Table 2). The percentage of beta-cells positive for p300
was decreased in subjects with T2D (P < 0.05; Fig. 6e
and f). These data therefore suggest that, under diabetes-
associated conditions, the decrease in p300 protein
expression in beta-cells occurs at a post-transcriptional
level. Many transcriptional factors and activators are
regulated by the 26S proteasome, which is one of the
major proteolysis systems of the cell and localizes to both
the cytoplasmic and nuclear compartments. Among
other, proteasomal degradation has been reported as a
mechanism involved in p300 turnover30. We evaluated
the levels of p300 content in INS-1E cells exposed to
high glucose for 48 h and treated for the last 8 h with
or without the proteasome inhibitor MG-132 (150 nM).
As expected, treatment with MG-132 led to accumulation
of ubiquitinated proteins in treated cells (darken
smears, Fig. 7a), confirming proteasome inhibition. This
treatment totally prevented p300 protein decrease
induced by high-glucose exposure (Fig. 7a), indicating
that glucotoxicity induces a proteasomal degradation of
p300. Similarly, treatment of cells with MG-132 prevented
p300 protein loss induced by the pro-inflammatory
cytokines (Fig. 7b), showing that the mechanism subser-
ving p300 alteration upon cytokine exposure is also a
proteasome-dependent degradation. Altogether the data
obtained with INS-1E cells and human beta-cells/islets
point to a proteasomal degradation involved in p300 loss
in pathological beta-cells.
Activation of melatonin signaling restores p300 levels in
beta-cells exposed to diabetic situations
Melatonin has been recently identified as a beta-cell
protective hormone31–34. Interestingly, melatonin’s actions
are purported to be mediated through connection with the
proteasomal degradation35, 36 and an increase in p300
expression37 as demonstrated in other cell types. We
therefore investigated the possible effect of melatonin on
p300 levels in beta-cells. Exposure of INS-1E cells to
melatonin (in concentration ranges 1–100 nM for 24 h)
led to increased p300 protein levels associated with
increased acetylation levels of Histones H4, particularly
evident at 100 nM melatonin concentration (Fig. 8a). We
therefore used a 100 nM melatonin concentration to
investigate whether melatonin would restore p300 levels in
beta-cells exposed to diabetic conditions. We evaluated
Fig. 5 p300 and histone H4 acetylation levels are decreased under chronic exposure to pro-inflammatory cytokines in beta-cells. a INS-1E
cells were exposed or not to pro-inflammatory cytokines mix (CK: 50 ng/ml TNFα, 0.2 ng/ml IL1β and 33 ng/ml IFNγfor 24 h (C, control). Protein levels
of p300, acetyl-Histone H4 (Ac-H4), cleaved caspase-3 (Cl. Casp-3), cleaved PARP (Cl. PARP) and CBP were analyzed by western blot. GAPDH was
used as loading control. b Quantification of p300, Ac-H4, Cl. Casp-3 and CBP protein levels. Data are expressed as mean ± SEM (n= 3); **P < 0.01,
***P < 0.001
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p300 protein levels in INS-1E cells exposed to either high
glucose for 48 h or the cytokines mixture for 24 h, and
incubated with melatonin for the final 14 h of culture. We
found that melatonin exposure preserved p300 protein
levels under high glucose conditions (Fig. 8b), and was also
protective against its loss induced by the pro-inflammatory
cytokines (Fig. 8c). Given the newly discovered role of
p300 in beta-cell survival and the well-described role of
melatonin in beta-cell protection under diabetic condi-
tions33, our data point to p300 as a new link between
melatonin signaling and beta-cell protection in T2D.
Discussion
Our study reveals for the first time that the histone
acetyl transferase p300 plays a key role in beta-cell
survival as demonstrated by the emergence of apoptosis
upon knockout or inhibition of p300. Both p300 enzyme
acetylation activity and protein binding activity therefore
seem important for beta-cell protection. In addition, data
obtained from the INS-1E beta-cell line as well as mouse
and human islets show that diabetes-related cytotoxic
conditions (proteotoxicity, glucotoxicity, lipotoxicity, and
inflammation) adversely affect p300 protein levels and
function. Our results unravel a new mechanism for glu-
cotoxicity- and cytokines-induced beta-cell apoptosis
involving proteasomal degradation of p300. Finally, we
found that activation of melatonin signaling preserves
p300 levels upon glucotoxicity and inflammation.
Among the mechanisms involved in p300 regulation,
proteasome-dependent degradation has been well described
Fig. 6 p300 mRNA levels are unchanged in INS-1E cells and human beta-cells/islets exposed to diabetic conditions but protein levels are
decreased in beta-cells in T2D. Levels of p300 mRNA were determined by quantitative RT-PCR and normalized to the geometric mean of the
expression levels of two housekeeping genes (Tbp, rHprt). a INS-1E cells cultured in 11 mM glucose (G11) or 30 mM glucose (G30) for 48 h. Data are
expressed as mean ± SEM (n= 4). b INS-1E cells exposed or not to pro-inflammatory cytokines mix (CK: 50 ng/ml TNFα, 0.2 ng/ml IL1β and 33 ng/ml
IFNγfor 24 h (C, control). Data are expressed as mean ± SEM (n= 3); *P < 0.05. c, d Beta-cell and islet transcriptomics analyses of p300 expression in
T2D subjects compared to normal glycemic controls (ND) are based on two independent human data sets GEO: GSE20966 (ND; n= 10 and T2D; n=
10) and GEO: GSE38642 (ND; n= 55 and T2D; n= 9) respectively. Data are expressed as mean ± SEM. e p300 protein levels were assessed by
immunofluorescence (p300, red; insulin, green; nuclei, blue) in human pancreatic tissue obtained at autopsy from non-diabetic subjects and subjects
with type 2 diabetes. f Percentage of beta-cells positive for p300 in each group. ND Non-Diabetic, T2D Subjects with type 2 diabetes. Data are
expressed as mean ± SEM; *P < 0.05
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in several studies and cell types30, 38, 39. The data obtained
using the INS-1E beta-cell line revealed the involvement of
this degradative pathway to downregulate p300 under
pathological conditions. Importantly, the decreased p300
protein levels in beta-cells of human subjects with T2D,
confronted with the data obtained from human data sets
showing similar p300 mRNA levels in beta-cells/islets from
T2D and non-diabetic subjects, further supports a post-
transcriptional regulation and degradation of p300.
Regarding the mechanism targeting p300 to degradation, it
has been shown that phosphorylation of p300 by the pro-
apoptotic kinase p38-MAPK is a mechanism by which p300
undergoes proteasomal degradation38, 39. Glucotoxicity and
exposure to pro-inflammatory cytokines, known to pro-
mote p38-MAPK activation in beta-cells33, 40, may therefore
lead to p300 phosphorylation and subsequent degradation.
Melatonin is a hormone produced and secreted from
the endocrine cells in the pineal gland and exhibits noc-
turnal production and secretion pattern. Key roles of
melatonin on beta-cell health and glucose homeostasis are
now confirmed by several recent studies31–34. The
pathogenesis of T2D is also associated with impaired
melatonin production and secretion34, 41. In addition,
genome-wide association scan studies have reported that
a variance in the gene encoding melatonin receptor 2
(MTNR1B) is associated with an increased risk of beta-cell
failure and T2D42, 43. Interestingly, melatonin has been
shown to decrease glucotoxicity-induced activation of
p38-MAPK in beta-cells to promote beta-cell survival33.
One can thus speculate that glucotoxicity (or cytokine
exposure)-induced p38-MAPK activation would lead to
p300 phosphorylation to promote its proteasomal degra-
dation, a mechanism likely to be blocked by melatonin to
protect beta-cells.
Similar to the role of p300 in neuron survival44, 45, our
study demonstrates a key role of p300 in beta-cell survival.
Among the genes involved in beta-cell survival, recent
studies suggest that the circadian clock is essential for
beta-cell functional integrity46–49. Since p300 has been
described to modulate clock genes BMAL1/CLOCK
transactivation ability10, we can consider that p300
maintains beta-cell survival via a positive modulation of
Fig. 7 Glucotoxicity or pro-inflammatory cytokines-induced p300 loss is mediated by proteasomal degradation in beta-cells. a p300,
Ubiquitin and GAPDH (loading control) protein levels in INS-1E cells cultured in 11 mM glucose (G11) or 30 mM glucose (G30) for 48 h in the presence
or not of MG-132 (150 nM) for the final 8 h. The graphs represent the quantification of p300 protein levels (n= 3). b p300 and actin (loading control)
protein levels in INS-1E cells exposed or not to pro-inflammatory cytokines mix for 24 h (C, control) in the presence of MG-132 (150 nM) for the final 8
h. The graphs represent the quantification of p300 protein levels. Data are expressed as mean±SEM (n= 3); *P < 0.05; **P < 0.01; ***P < 0.001
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the circadian clock. Moreover, since melatonin also reg-
ulates clock gene expression in beta-cells50, 51, we can
hypothesize that melatonin signaling would favor beta-
cell clock gene expression and activation, at least in part,
through stabilization of p300 to ultimately protect beta-
cells from cytotoxic injury.
Whereas p300 plays an important role in beta-cell
survival and seems therefore controlling expression of
genes crucial for such purpose, we cannot exclude that
specific environments and interacting partners will target
p300 to other genes in beta-cells. Indeed, it has been
reported that glucose stimulates the recruitment of p300
to the promoter region of the Txnip gene in human
islets52 and that p300 knockout prevents the expression of
this pro-apoptotic factor Txnip in beta-cells exposed to
high glucose53. Whereas the study from Bompada et al.53
aimed to investigate the role of p300 knock-out under
pathological conditions (i.e., glucotoxicity), we rather
questioned the role of p300 knock-down or inhibition
under physiological conditions. This may therefore
explain the discrepancy between our results and the
above-mentioned studies52, 53. Nevertheless, consistent
with the role of p300 in Txnip gene expression in beta-
cells52, 53, evaluation of Txnip expression under p300
knock-down or inhibition revealed that the basal levels of
Txnip were diminished (Supplemental Fig. 5). Despite this
decrease in the pro-apoptotic factor Txnip, we clearly
detected apoptosis under these conditions. Thus, it is
likely that knock-down/inhibition of p300 under normal
conditions blocks not only the expression of pro-
apoptotic factors such as Txnip, but also the expression
of survival factors which overall favors the emergence of
beta-cell apoptosis. On the other hand, since our gluco-
toxicity conditions led to a partial decrease in p300, the
remaining pool of p300 available may thus be redirected
to control other genes such as Txnip. At last, our study
Fig. 8 Activation of melatonin receptor signaling preserves p300 levels in beta-cells exposed to diabetes-related stress. a INS-1E cells were
exposed to 1, 10, 100 nM melatonin during 24 h (C, control cells). Protein levels of p300 and acetylated histone H4 (Ac-H4) were analyzed by western
blot. GAPDH was used as loading control. The graphs represent the quantification of p300 and Ac-H4 protein levels (n= 3–4). b p300 and actin
(loading control) protein levels in INS-1E cells cultured in 11 mM glucose (G11) or 30 mM glucose (G30) and exposed for the final 14 h to media
containing melatonin (100 nM) or not. The graphs represent the quantification of p300 protein levels (n= 3). c p300 and actin (loading control)
protein levels in INS-1E cells exposed or not to pro-inflammatory cytokines mix (CK: 50 ng/ml TNFα, 0.2 ng/ml IL1β and 33 ng/ml IFNγ for 24 h (C,
control) and incubated for the final 14 h to media containing melatonin (100 nM) or not. The graphs represent the quantification of p300 protein
levels (n= 3). Data are expressed as mean ± SEM; *P < 0.05, **P < 0.01, ***P < 0.001. NS, non-significant
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and the one from Bompada et al.53. agree that blockade of
p300 under normal condition leads to beta-cell apoptosis
and altered insulin response to glucose (decreased sti-
mulation index with elevated basal insulin secretion).
Basal insulin secretion and the subsequent inability to
further increase insulin secretion in response to glucose is
not uncommon in individuals with T2D. Further investi-
gations are required to determine the potential involve-
ment of p300 in insulin gene expression and/or insulin
exocytosis.
Although p300 and CBP are highly homologous pro-
teins (63% homology at the amino acid level) and have
some interaction partners in common, they have distinct
functions and cannot always replace each other9. Inter-
estingly, our results show that glucotoxicity or cytokines
specifically reduced p300 protein levels, without inducing
any decrease or increase in CBP to compensate p300 loss,
suggesting specificity in the action of high glucose and
cytokines to alter p300 in beta-cells. While the literature
often fails to distinguish between p300 and CBP (or other
HATs), additional studies are required to identify genes
that are specifically controlled by p300 and to determine
p300-interacting partners in beta-cells in vivo.
Loss-of-function mutations in EP300 (p300) or CREBBP
(CBP) are known causes of the Rubistein-Taybi syndrome,
a rare congenital developmental disorder54. As mentioned
in earlier articles, few patients with Rubistein-Taybi syn-
drome developed early onset glucose phenotypes55, 56. It
would therefore be of great interest to follow glucose
regulation in a larger cohort of Rubistein-Taybi syndrome
patients with specific p300 mutations to further ascertain
association between p300 loss and diabetes-like pheno-
types in humans.
Our study demonstrates for the first time a key role of
p300 in beta-cell survival and function and its alteration
under pathological situations. We further show that p300
proteasomal degradation plays a role in the pathophy-
siology of diabetes and constitutes a potential site for
therapeutic intervention. Finally, melatonin signaling may
represent a strategy for the maintenance of p300 integrity
in order to preserve a functional beta-cell mass in T2D.
Materials and methods
Animal models
C57BL/6J mice were purchased from Charles River
(L’Arbresle, France). All experiments were performed
using 4-month-old male mice, except when indicated. All
animal studies complied with the animal welfare guide-
lines of the European Community and were approved by
the Direction of Veterinary Departments of Hérault and
Nord, France (59-350134).
Transgenic mice were bred and housed at the University
of California, Los Angeles (UCLA) animal housing facility.
The institutional animal care and use committee of the
UCLA approved all experimental procedures. Animals
were maintained on a 12-h day/night cycle with Harlan
Teklad Rodent Diet 8604 (Madison, WI, USA) and water
ad libitum. Males were used for the experiments. The
generation and characterization of transgenic mice
homozygous for human-IAPP (h-TG: FVB-Tg(IAPP)
6Jdm/Tg(IAPP)6Jdm) and rodent-IAPP (r-TG: FVB/N-Tg
(Iapp)6Wcs/Tg(Iapp)6Wcs) have been described pre-
viously57. Control WT (FVB) mice were originally pur-
chased from Charles Rivers Laboratory (Wilmington, MA,
USA) and bred at UCLA. Characteristics of mice used for
the experiments are listed on Supplemental Table 1.
Mouse islet isolation
Islets were isolated from mice after collagenase diges-
tion of the pancreas58, and were used either immediately
or after overnight culture. Islets were washed with ice-
cold PBS and lysed in NP40 lysis buffer (0.5% Nonidet P-
40, 20 mM Tris-HCl, pH 7.5, 150mM NaCl, 2 mM
MgCl2, 1 mM dithiothreitol, 5 mM NaF, 1 mM Na3VO4,
and protease inhibitors [Sigma-Aldrich, St. Louis, MO,
USA]). After 10 min of incubation in lysis buffer on ice,
islets were sonicated for 10 s and centrifuged at 10,000 r.p.
m. at 4 °C for 10min to remove insoluble materials.
Supernatant was stored at −20 °C until use for subsequent
protein determination by BCA assay (Bio-Rad, Marnes-la-
Coquette, France) and western blotting.
In the experiments testing the effect of p300 inhibitor,
islets were used after an overnight culture in RPMI-1640
medium containing 11mM glucose supplemented with
10% heat-inactivated FBS, 2 mM glutamine, 10 mM
HEPES, 100 IU/ml penicillin and 100 μg/ml streptomycin
(Life technologies, Courtaboeuf, France). Islets were then
treated with 30 μM C646 (Merck, Fontenay-sous-Bois,
France) for 48 h. To minimize the effects of subjective
bias, groups of islets were randomly distributed in tubes.
No blinding was done. Immunostaining in islets is
described in Supplemental materials and methods.
Human islets
Experiments involving usage of human islets were per-
formed in agreement with the local ethic committee
(CHU, Montpellier) and the institutional ethical com-
mittee of the French Agence de la Biomédecine (DC Nos.
2014-2473 and 2016-2716). Informed consent was
obtained from all donors. Pancreases were harvested from
three brain-dead non-diabetic donors. Isolated islets were
prepared by collagenase digestion followed by density
gradient purification at the Laboratory of Cell Therapy for
Diabetes (Institute for Regenerative Medicine and Bio-
therapy, Montpellier, France), according to a slightly
modified version of the automated method59. Following
isolation, human islets were cultured for recovery for
3 days at 37 °C, in a 5% CO2 atmosphere, in CMRL 1066
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medium (Life Technologies) containing 5.6 mM glucose
supplemented with 10% FBS, 2 mM glutamine, 100 IU/ml
penicillin, and 100 μg/ml streptomycin. Islets were then
incubated for 72 h in CMRL 1066 medium (without FBS)
containing 5.6 mM or 30 mM glucose ± 0.5 mM palmitate
(see palmitate preparation in Mancini et al.60). At the end
of the experiment, islets were washed with cold PBS and
lysed for 10 min at 4 °C in NP40 lysis buffer, sonicated for
10 s and centrifuged at 10,000 r.p.m. for 10min.
Human pancreatic sections and immunostaining
Human pancreas was procured from the Mayo Clinic
autopsy archives with approval from the Institutional
Research Biosafety Board. Informed consent was obtained
from all donors. Clinical characteristics of human donors
are listed on Supplemental Table 2. Paraffin-embedded
pancreatic sections were co-immunostained by immuno-
fluorescence for insulin (ab7842; 1:100; Abcam, Cam-
bridge, MA, USA), p300 (sc-48343; 1:100; Santa Cruz
Biotechnology, Dallas, TX, USA) and cover slipped with
Vectashield-DAPI mounting medium (Vector Labora-
tories, Burlingame, CA, USA), stored in dark at 4 °C, and
analyzed within 1–3 days after staining. Blinded slides
were viewed, imaged and analyzed using a Zeiss Axio
Observer Z1 microscope (Carl Zeiss Microscopy LLC, NY,
USA) and ZenPro software (Carl Zeiss Microscopy, LLC).
To quantify percentage of p300 positive beta-cells, 500
beta-cells per pancreatic section were examined in detail
and counted at ×20 magnification for the presence/
absence of p300 immunoreactivity.
Cell culture
The rat beta-cell line INS-1E was provided by Dr. P.
Maechler (Department of Cell Physiology and Metabo-
lism, University of Geneva, Geneva, Switzerland)61. INS-
1E cells were grown in RPMI-1640 medium with 11mM
glucose supplemented with 7.5% heat-inactivated FBS, 1
mM sodium pyruvate, 50 μM β-mercaptoethanol, 2 mM
glutamine, 10 mM HEPES and 100 IU/ml penicillin and
100 μg/ml streptomycin (Life Technologies) at 37 °C in a
humidified 5% CO2 atmosphere. No mycoplasma con-
tamination was detected.
-For glucotoxicity experiments, INS-1E cells were
cultured in complete RPMI 1640 medium (Life Tech-
nologies) containing 11 or 30 mM glucose for 72 h.
-For pro-inflammatory cytokine exposure, INS-1E cells
were incubated in a cytokine mix (100 IU/ml IL-1β
(0. 2 ng/ml), 500 IU/ml TNF-α (50 ng/ml) and 100 IU/ml
IFN-γ (33 ng/ml) for 24 h. Murine recombinant IFN-γ
were from Invitrogen (Life Technologies), murine IL-1β
and TNF-α from PeproTech.
The proteasome inhibitor MG-132 (dissolved in DMSO;
Millipore, Saint-Quentin-en-Yvelines, France) was added
at 150 nM during the last 8 h of the treatment. Melatonin
100 nM (dissolved in DMSO; Bachem, Weil AM Rhein,
Allemagne) was added during the last 14 h of the
treatment.
-In the experiments testing the effect of p300 inhibitor,
cells were treated with 30 μM C646 (dissolved in DMSO)
for 24 h.
At the end of the experiment, cells were washed with
cold PBS and lysed for 10min at 4 °C in NP40 lysis buffer
and centrifuged at 10,000 r.p.m. for 10min.
p300 siRNA
p300 expression was silenced in INS-1E cells using
Silencer Select siRNA duplexes designed for rat Ep300
(s220367, Life Technologies). Cells were seeded in 6-well
plates at 800,000 cells/well and grown overnight to reach
40–50% confluency. The next day, lipofectAMINE3000-
siRNA complexes were prepared according to the man-
ufacturer’s instructions. p300 siRNA duplexes were tested
at final concentrations of 10, 25 or 50 nM. Cells were
transfected with p300 siRNA or control siRNA (scramble)
in Opti-MEM (Life Technologies) for 24 h before
switching to fresh culture medium. After 48 or 72 h of
transfection, cells were washed with cold PBS and lysed
for 10min at 4 °C in NP40 lysis buffer and centrifuged at
10,000 r.p.m. for 10min.
Western blotting
Proteins (25–50 μg/lane) were separated on a 4–12%
Bis-Tris (or 3-8% Tris-Acetate) NuPAGE gel and blotted
onto a PVDF membrane (FluoroTrans; VWR, Fontenay-
sous-Bois, France). Membranes were probed overnight at
4 °C with primary antibodies against cleaved caspase-3
(Cell signaling, Leiden, Netherlands, 9661), cleaved PARP
(Cell signaling, 9542), CBP (Cell signaling, 7389), Ubi-
quitin (Cell signaling, 3936), Phospho-Histone H2A.X
(Ser 139; Cell signaling, 9718), phosho-CREB (Ser 133;
Cell signaling, 9198) and GAPDH (Cell signaling, 5174),
p300 (Millipore, 05-257), acetyl-Histone H3 (Millipore,
06-599), acetyl-Histone H4 (Millipore, 06-866), Actin
(Sigma, A5441), Txnip (Cell signaling, 14715), Pdx1 (Cell
signaling, 5679), Nkx6.1 (Cell signaling, 54551). Horse-
radish peroxidase-conjugated secondary antibodies were
from Cell signaling. Proteins were visualized by enhanced
chemiluminescence (Millipore) on ChemiDoc camera
(Bio-Rad) and protein expression levels were quantified
using the ImageJ software.
RNA isolation, RT-PCR, real-time quantitative PCR
Total RNA was extracted using the RNeasy Mini Kit
(Qiagen, Courtaboeuf, France) performing on-column
DNase digestion with RNase-Free DNase Set (Qiagen)
according to the manufacturer’s instructions. RNA (1 μg)
was used for preparation of single-stranded cDNA using
Superscript III Reverse transcriptase (Life Technologies)
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by the oligo-dT priming method. Real-time quantitative
PCR was performed with the LightCycler FastStart DNA
Master SYBR Green I kit (Roche, Meylan, France) and the
LightCycler PCR equipment (Roche). The oligonucleotide
primers were: 5′-GAACAAGGGCATTTTGCCA-3′+ 5′-
TAGCGAGCTGTGAAAGCATTGA-3′ for rat Ep300. All
measurements were normalized to the geometric mean of
the expression levels of two housekeeping genes: rat Hprt
(5′-TGACTATAATGAGCACTTCAGGGATT-3′+ 5′-
TCGCTGATGACACAAACATGATT-3′) and rat Tbp
(5′-GTTGACCCACCAGCAGTTCAG-3′+ 5′-AATCCA
GGAAATAATTCTGGCTCATA).
Insulin secretion
Cells were pre-incubated for 2 h in KRB buffer58 con-
taining 1.4 mM glucose, followed by a 1h incubation at
1.4 mM or 16.7 mM glucose. Supernatant from the incu-
bation buffers were collected and cleared by centrifuga-
tion. Insulin content extraction was performed using acid
ethanol. Insulin release and contents were measured by
Homogenous Time Resolved Fluorescence (HTRF) (Cis-
bio bioassays, Codolet, France) according to the manu-
facturer’s instructions. HTRF signals were measured using
Pherastar FS (BMG Labtech, Ortenberg, Germany)
microplate reader. Insulin release was then normalized to
insulin content. The insulin stimulation index was cal-
culated as the ratio of stimulated to basal insulin secre-
tion, both of which are normalized to insulin content
Human islet gene expression
To identify transcriptomic datasets from human pan-
creatic islets, GEO analysis from the NCBI was performed
using “human islet T2D” as keywords and filtered with
“Datasets”. Two datasets were selected based on the
highest number of samples (GEO: GSE38642;29 and GEO:
GSE2096628). Datasets were downloaded from the GEO
and analyzed.
Statistical analysis
Results are expressed as the means±SEM. for n inde-
pendent experiments, as indicated in figure legends. Sta-
tistical analyses were carried out using Student’s t-test or
one-way ANOVA followed by Sidak’s post hoc test for
multiple comparisons using GraphPad Prism 7. A P-value
of < 0.05 was taken as evidence of statistical significance
(*P < 0.05, **P < 0.01, ***P < 0.001).
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Mice n Age (wks) Weight (g)
Fasting glucose 
(mg/dl)
WT 6 9-10 24.2 ± 0.4 76.6 ± 6.5
r-TG 6 9-10 24 ± 0.4 44.5 ± 4.1
h-TG 4 9-10 23.2 ± 0.5 79.2 ± 7.6
Supplemental Table 1. Characteristics of mice used for islet subcellular fractionation in Fig.2.
Human donors n
Age 
(years)
BMI 
(kg/m2)
Fasting plasma 
glucose (mg/dl)
HbA1c
(%)
Non-Diabetic 4 75 ± 6 25 ± 1 82 ± 4 n/a
Type 2 Diabetes 4 78 ± 6 33 ± 1 196 ± 31 7 ± 1
Supplemental Table 2. Clinical characteristics of human donors used for immunostaining analysis of p300 in Fig.6.
Values are mean ± SE.
Supplemental Figure 1. Inhibition of p300 leads to beta-cell apoptosis in mice and humans. (A) TUNEL staining was assessed by
immunofluorescence (TUNEL, red; insulin, green; glucagon, white; nuclei, blue) in isolated mouse islets treated or not with C646 (30 mM for 72h).
(B) Percentage of beta-cells and alpha-cells positive for TUNEL in each group. Data are expressed as mean ± SEM; *P < 0.05. (C) TUNEL
staining was assessed by immunofluorescence (TUNEL, red; insulin, green; glucagon, white; nuclei, blue) in human islets treated or not with C646
(30 mM for 72h) (n=2 human donors). (D) Percentage of beta-cells and alpha-cells positive for TUNEL for each human donor (HI-1 and HI-2) in
each group. The fold of change indicated is versus “Vehicle”.
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Supplemental Figure 2. Inhibition of p300 by C646 alters beta-cell function. (A) INS-1E cells were treated with C646 (30 mM for 24h) (or with
0.003% DMSO as vehicle). Levels of Pdx1 and Nkx6.1 were assessed by western blot. Actin was used as loading control. The graphs represent the
quantification of the western blots (n=3). Data are expressed as mean ± SEM; *P<0.05 vs Vehicle. (B) INS-1E cells were treated with C646 (30 mM
for 24h) (or with 0.003% DMSO as vehicle). Following a 2-h quiescent period in Krebs 1.4 mM glucose (G1.4), cells were stimulated with 16.7 mM
glucose (G16.7) during 1h at 37°C; (G1.4 refers to non-stimulated cells). Insulin secretion and insulin content were measured by HTRF
(Homogeneous Time Resolved Fluorescence). The insulin content remained unchanged. The graph represents insulin secretion normalized to insulin
content. (C) The graph represents the stimulation index (ratio G16.7: G1.4). Data are expressed as mean ± SEM (n=4); *P<0.05.
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Supplemental Figure 3. Knock-down of p300 by siRNA (72h) leads to beta-cell apoptosis. (A) INS-1E cells were transfected with
scramble (Scr) or p300 siRNA (Si) (10 or 50 nmol/L as indicated) during 72h; (C, non-transfected cells). p300 and cleaved caspase-3 (Cl.
Casp-3) protein levels were analyzed by western blot. Actin was used as loading control. (B) Acetyl-Histone H3 (Ac-H3) protein levels were
analyzed by western blot. Actin was used as loading control.
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Supplemental Figure 4. Knock-down of p300 by siRNA leads to altered glucose-induced insulin secretion in beta-cells. (A) INS-1E cells
were transfected with scramble (Scr) or p300 siRNA (Si) (10 or 50 nM) during 72h; (C, non-transfected cells). Following a 2-h quiescent period in
Krebs 1.4 mM glucose (G1.4), cells were stimulated with 16.7 mM glucose (G16.7) during 1h at 37°C; (G1.4 refers to non-stimulated cells).
Insulin secretion and insulin content were measured by HTRF (Homogeneous Time Resolved Fluorescence). The insulin content remained
unchanged. The graph represents insulin secretion normalized to insulin content. (B) The graph represents the stimulation index (ratio G16.7:
G1.4). Data are expressed as mean ± SEM (n=3); *P<0.05.
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Supplemental Figure 5. Txnip protein expression is decreased in INS-1E cells under inhibition or knock-down of p300. (A) INS-1E cells
were treated with C646 (30 mM for 24h) (or with 0.003% DMSO as vehicle). Levels of Txnip were assessed by western blot. Actin was used as
loading control. The graph represents the quantification of the western blot (n=4). (B) INS-1E cells were transfected with scramble (Scr) or p300
siRNA (Si) (50 nM) during 48h; (C, non-transfected cells). Txnip protein levels were analyzed by western blot. Actin was used as loading control.
The graphs represent the quantification of the western blot (n=3). Data are expressed as mean ± SEM; *P<0.05, **P<0.01.
SUPPLEMENTAL MATERIALS AND METHODS 
 
TUNEL and immunostaining on isolated mouse islets and human islets. Islets were isolated 
from four 4-month-old male mice and treated with C646 (30 M, 72h) or DMSO as vehicle 
(130 islets per condition). Human islets obtained from 2 non-diabetic donors were treated 
according the same procedure. Islets were then washed twice in PBS and transferred into 3.7% 
paraformaldehyde (Sigma-Aldrich) in PBS for fixation during 4h. After 2 washes in PBS, islets 
were colored in 0.1% neutral red, washed twice in PBS and embedded in 24% agar. Cubes of 
agar containing batches of islets were fixed overnight into 3.7% paraformaldehyde, washed 
with PBS before being transferred into 70% ethanol and then processed for paraffin embedding. 
The percentage of apoptotic beta-cells (TUNEL-positive and insulin-positive cells) and 
apoptotic alpha-cells (TUNEL-positive and glucagon-positive cells) was determined on 4 µm-
thick sections using the In Situ Cell Death Detection Kit - TMRred (Roche Diagnostics) 
following the manufacturer’s instructions. Sections were then incubated 1h at room temperature 
with primary antibodies (anti-insulin, 1/200, Abcam; anti-glucagon, 1/400, Sigma), followed 
by 1h at room temperature with secondary antibodies and DAPI. Sections were mounted in 
Mowiol (Sigma-Aldrich). Islets were imaged using a 20X objective from AxioImager 
microscope (Zeiss) using the Zen Blue software. Islets were imaged and saved in “.czi” (rather 
than “tiff”) format allowing to save the entire image parameters and were reopened and 
quantified using ImageJ (National Institutes of Health, Bethesda, MD). To quantify percentage 
of TUNEL positive beta-cells, 4000-6000 beta-cells per mouse were examined in detail and 
counted for presence/absence of TUNEL immunoreactivity. To quantify percentage of TUNEL 
positive alpha-cells, 600-1000 alpha-cells per mouse were examined for TUNEL 
immunoreactivity. To quantify percentage of TUNEL positive beta-cells and alpha-cells, 4500-
6000 human beta-cells and 600-700 human alpha-cells were examined in detail and counted for 
presence/absence of TUNEL immunoreactivity. 
